Evoke Pharma (NASDAQ:EVOK) shares rocketed 90% early Monday on positive data for its nasal drug Gimoti in the treatment of ...

diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the ...

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-yearStrong growth in key commercial metrics, including ...

CEO Matt D'Onofrio emphasized the value of Pyszczymuka's experience in commercial strategy as Evoke seeks to expand access to its nasal spray treatment, GIMOTI, for diabetic gastroparesis.

GIMOTI® is the only FDA-approved nasal spray formulation of metoclopramide, providing an alternative to oral and injectable forms. The company maintains an impressive gross profit margin of 96.55 ...

Good afternoon, and welcome to the Evoke Pharma fourth quarter and full-year 2024 earnings conference call. (Operator Instructions) Please be advised that today's call is being recorded. I would now ...

The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

The addition of Pyszczymuka, a seasoned commercial leader with a track record in pharmaceuticals, is a strategic move by Evoke as it aims to bolster its commercial strategy and growth potential, ...